Fiverings Co., Ltd. Report issue

For profit Phase 1 Phase 2
Founded: Osaka Japan (2013)

Organization Overview

First Clinical Trial
2014
NCT02096614
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Fiverings Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Esophageal Neoplasms (Phase 1)

Esophageal Squamous Cell Carcinoma (Phase 1)

Kidney Neoplasms (Phase 1)

Mouth Neoplasms (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 8